Technical Data

V2121-60B
Clone Type
Monoclonal
Host
Mouse
Isotype
IgG1
Clone Number
9G300 (13C4)
Grade
Affinity Purified
Applications
E N WB
Shipping Temp
Blue Ice
Storage Temp
-20°C
Mouse Anti-Verotoxin I-B subunit (Shiga-like, SLT-1b)
Verotoxin 1

Verotoxins are also called Shiga-like toxins (SLTs). Enterohemorrhagic Escherichia coli (EHEC) strains which are primarily of serotypes 0157:H7, 026:H11 and O111:H8 have been incriminated as etiologic agents of hemorrhagic colitis and Hemolytic-uremic syndrome, a generalized disease characterized by acute renal failure, thrombocytopenia and micro- angiopathic hemolytic anemia. There are several distinct E.coli SLTs. SLT-I and SLT-II are produced by EHEC. SLT-I and Shiga toxin share > 99% deduced amino acid sequence homology, whereas SLT-I and SLT-II share about 60% deduced amino acid sequence homology. SLT-I and SLT-II are antigenically distinct. The protein structure of the toxin consists of two domains: the A polypeptide that inhibits protein synthesis by targeting ribosomes, and the B polypeptide pentamer that binds to the eukaryotic cell receptor globotriaosylceramide (Gb3) leading to receptor-mediated endocytosis.

Applications
Suitable for use in Western Blot, ELISA and Inhibition. Other applications not tested.
Recommended Dilution
Western Blot: 1:10 Inhibition: in vitro dilutions should be made according to the amount of toxin to be inactiviated. Optimal dilutions to be determined by the researcher.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
Purified, biologically active SLT from E. coli H30
Form
Supplied as a liquid in PBS, 0.1% BSA.
Purity
Purified by Protein G affinity chromatography
Specificity
Recognizes the 1-B subunit of Verotoxin (Shiga-like toxin-1).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

References
1. Strockbine, N et al; Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 1985, 50: 695. |2. Smith, M et al; Development of a hybrid Shiga holotoxoid vaccine to elict heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006, 24:4122. |3. Smith, M et al; The 13C3 monoclonal antibody that neutralizes Shiga toxin type 1 (Stx1) recognizes three regions on the Stx1 subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect Immun 2006, 74:6992.
USBio References
No references available
United States Biological | 4 Technology Way | Salem, MA 01970
Phone 800-520-3011 | Fax 978-594-8052 | Website www.usbio.net